Legal
Sanofi Cuts Zantac Risk With Arbitration Win Over Boehringer
This article is for subscribers only.
Sanofi defeated Boehringer Ingelheim GmbH in an arbitration proceeding over legal responsibilities tied to controversial heartburn medicine Zantac.
The French drugmaker is not liable to indemnify BI for any potential losses related to ongoing Zantac litigation in the US, where thousands of plaintiffs have alleged that the heartburn medicine causes cancer, according to a statement Tuesday. Sanofi shares rose as much as 2.5% in Frankfurt.